Atlas Trials

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Clinical trial NCT04722575 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04722575
Sponsor
Fondazione Melanoma Onlus
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2020-12-03
Primary completion
2023-12-15
Enrollment
95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.